Different radiopharmaceuticals have been used in PET/CT and PET/MRI of nontumoral bone and soft-tissue pathologic abnormalities of the musculoskeletal system, including radiotracers studying metabolism of glucose, amino acid, and nucleotide; bone and cell turnover metabolites; and cellular receptors and transporters. Fluorine-18-FDG, which follows the in vivo glucose metabolism, is by far the most common radiopharmaceutical used for this purpose.MRI offers higher specificity, combining 18F-NaF PET with MRI can be an excellent imaging tool to approach osteoblastic osseous lesions.